Presley Gerber's Ibogaine Treatment Raises Concerns Over Cardiac Risks
Presley Gerber, the son of supermodel Cindy Crawford, underwent treatment with the psychedelic ibogaine months before his death at the age of 27. This treatment has raised alarms among experts due to its potential severe cardiac risks. Gerber documented his experience with an "ibogaine flood dose" at a wellness retreat in March, sharing insights into his struggles with addiction. His passing was confirmed on September 21, 2026, at a rehabilitation center, although the cause of death has not been disclosed, and there is no established evidence linking ibogaine to his death.
Ibogaine, derived from the Tabernanthe iboga shrub native to Central Africa, produces intense psychedelic effects and has garnered interest for its potential to alleviate drug cravings and withdrawal symptoms. However, it is classified as a Schedule I controlled substance in the U.S., indicating it has no accepted medical use and cannot be legally prescribed. Despite the lack of formal approval, research into ibogaine's benefits continues, although it is accompanied by significant concerns regarding cardiac toxicity.
A systematic review highlighted the effectiveness of ibogaine for substance-use disorders but cautioned about its association with cardiac risks, including QT prolongation and potentially fatal ventricular arrhythmias. Experts emphasize the necessity of rigorous cardiovascular monitoring during treatment. Additionally, some studies have explored ibogaine's effects beyond addiction, indicating potential improvements in PTSD, depression, and anxiety among military veterans.
Gerber shared his personal reflections on his ibogaine experience, describing it as "terrifying" yet transformative. He expressed a desire for it to be his last treatment, emphasizing the importance of self-love and trust in the process. His family, including his sister Kaia Gerber, publicly supported him during his treatment journey, highlighting the emotional weight of his struggles.
Medical sources have noted that while ibogaine shows promise, it remains an experimental treatment area. The excitement surrounding its potential can sometimes overshadow the science, and there are already effective, evidence-based treatments for opioid-use disorder available. The complexities of ibogaine's effects and the risks associated with its use necessitate further research to establish safe and effective treatment protocols. As the conversation around ibogaine continues, it is crucial to balance the hope it offers with the reality of its risks, ensuring that anyone considering it is fully informed of the potential dangers involved.




